Julia Feldman, NP
Nurse Practitioner · Franklin, MANPI 1164076899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- Valinor Pharma, LLC$567
- Collegium Pharmaceutical, Inc.$380
- Pfizer$314
- Azurity Pharmaceuticals, Inc.$274
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,674100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 103 | $1,516 |
| AbbVie(2 entities) | 73 | $1,413 |
| Valinor Pharma, LLC | 33 | $567 |
| Collegium Pharmaceutical, Inc. | 33 | $380 |
| Pfizer | 15 | $314 |
| Azurity Pharmaceuticals, Inc. | 14 | $274 |
| Lilly USA, LLC | 8 | $191 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $177 |
| Averitas Pharma Inc. | 6 | $174 |
| Arbor Pharmaceuticals, Inc. | 7 | $169 |
| Indivior Inc. | 9 | $165 |
| Novo Nordisk | 7 | $147 |
| Hikma Pharmaceuticals USA | 6 | $116 |
| Lundbeck LLC | 4 | $103 |
| Redhill Biopharma Inc. | 5 | $103 |
| Tersera Therapeutics LLC | 4 | $101 |
| Vertex | 4 | $85 |
| Johnson & Johnson | 3 | $83 |
| Bioventus LLC | 3 | $68 |
| Medtronic | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $49 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Si-bone, Inc. | 2 | $46 |
| Vertos Medical, Inc. | 1 | $44 |
| Novartis | 2 | $40 |
| Spinal Simplicity, LLC | 2 | $37 |
| Orexo US, Inc. | 2 | $34 |
| Painteq LLC | 1 | $33 |
| Fidia Pharma USA Inc. | 2 | $30 |
| SPR Therapeutics, Inc | 1 | $24 |
| Relievant Medsystems, Inc. | 1 | $24 |
| Saluda Medical Americas, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$6,674 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 30 | $94,137 |
| BelbucaBuprenorphine Hcl | 122 | $94,131 |
| Buprenorphine | 125 | $29,512 |
| MovantikNaloxegol Oxalate | 61 | $24,965 |
| OxycontinOxycodone Hcl | 55 | $22,332 |
| Xtampza ErOxycodone Myristate | 40 | $14,587 |
| MounjaroTirzepatide | 12 | $13,977 |
| OzempicSemaglutide | 11 | $10,084 |
| ZtlidoLidocaine | 19 | $9,822 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 355 | $9,795 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 352 | $9,399 |
| Oxycodone Hcl | 378 | $6,592 |
| ButransBuprenorphine | 11 | $3,960 |
| Pregabalin | 113 | $3,378 |
| Fentanyl | 32 | $3,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $380 | $108,718162 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,516 | $94,13730 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $116 | $33,292194 claims |
| Redhill Biopharma Inc.Movantik | $103 | $24,96561 claims |
| Lilly USA, LLCMounjaro | $191 | $13,97712 claims |
| Novo NordiskOzempic | $147 | $10,08411 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $47 | $9,82219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Franklin
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
- Lauren BurkeBoston$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.